Biocogniv has filed a notice of an exempt offering of securities to raise $11,793,106.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Biocogniv is raising $11,793,106.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Artur Adib played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Biocogniv
Recent advances in artificial intelligence have enabled a new generation of companies and products that are poised to change healthcare forever. From drug discovery to early disease detection, AI is shaping a future where care is personalized, preemptive, and affordable. Biocogniv enables a key part of this future by combining laboratory medicine, state-of-the-art AI, and evidence-based acute care, to reduce preventable hospital deaths, morbidities, and cost of care.
To learn more about Biocogniv, visit http://biocogniv.com/
Contact:
Artur Adib, Chief Executive Officer
802-349-1935
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.